Efficacy and Safety of mizoribine for MPO-ANCA associated vasculitis; A multicenter randomized controlled trial (Mizoribin for ANCA RPGN Relapse-Prevention study:MARPGN study)

Authors
Category Primary study
JournalUMIN Clinical Trials Registry
Year 2007
INTERVENTION: treatment with mizoribine according to the GFR once a day no treatment with mizoribine CONDITION: MPO‐ANCA associated vasculitis PRIMARY OUTCOME: BVAS score, time from remmision to relapse, relapse rate SECONDARY OUTCOME: MPO‐ANCA titer, CRP, GFR, amount dose of corticosteroid through the study INCLUSION CRITERIA: Patients in remmision state of ANCA‐associated vasculitis
Epistemonikos ID: e485000fe3779666319464157f2508bcc798ff4a
First added on: Aug 21, 2024